HCW Biologics Amends Proxy Statement, Removes Equity Plan Proposal

What Happened

• HCW Biologics Inc. filed an Amendment No. 1 to its Preliminary Proxy Statement (Amendment) on September 9, 2026, disclosed in an 8‑K filed September 10, 2026.
• After considering stockholder feedback, the company’s board decided not to seek stockholder approval of Proposal No. 2 from the original PRE 14A (filed Sept. 8, 2026). Proposal No. 2 would have sought approval of an amended performance‑based equity plan for eligible officers, directors and employees. The Amendment removes that proposal and updates the Special Meeting date, the record date, and certain other dates in the original proxy.

Key Details

• Amendment filed: September 9, 2026; Original PRE 14A filed: September 8, 2026.
• Proposal removed: Proposal No. 2 (amendment to company’s performance‑based equity plan for officers, directors, employees).
• Meeting logistics changed: the Special Meeting date, record date for voting, and certain other dates in the original proxy were revised.
• No other substantive changes were made to the original preliminary proxy statement, per the filing.

Why It Matters

• Removing the equity plan proposal means stockholders will not vote on the proposed performance‑based equity plan at the upcoming special meeting, which affects potential future equity grants and any related dilution or incentive‑structure changes.
• Changes to the special meeting and record dates affect who is eligible to vote and the timing for investor action (e.g., meeting participation or proxy voting).
• The filing signals responsiveness to stockholder feedback; investors should review the amended proxy to confirm the updated meeting logistics and any remaining items up for vote.